Literature DB >> 7464559

Abnormal preponderance of sialylated apolipoprotein CIII in triglyceride rich lipoproteins in type V hyperlipoproteinemia.

M L Kashyap, B A Hynd, K Robinson, P S Gartside.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7464559     DOI: 10.1016/0026-0495(81)90158-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


× No keyword cloud information.
  5 in total

1.  Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.

Authors:  Adriaan G Holleboom; Helen Karlsson; Ruei-Shiuan Lin; Thomas M Beres; Jeroen A Sierts; Daniel S Herman; Erik S G Stroes; Johannes M Aerts; John J P Kastelein; Mohammad M Motazacker; Geesje M Dallinga-Thie; Johannes H M Levels; Aeilko H Zwinderman; Jonathan G Seidman; Christine E Seidman; Stefan Ljunggren; Dirk J Lefeber; Eva Morava; Ron A Wevers; Timothy A Fritz; Lawrence A Tabak; Mats Lindahl; G Kees Hovingh; Jan Albert Kuivenhoven
Journal:  Cell Metab       Date:  2011-12-07       Impact factor: 27.287

2.  Altered glycosylation and sialylation of serum proteins and lipid bound sialic acids in chronic renal failure.

Authors:  B K Kishore; F Gejyo; M Arakawa
Journal:  Postgrad Med J       Date:  1983-09       Impact factor: 2.401

3.  Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia.

Authors:  A F Stalenhoef; P N Demacker; J A Lutterman; A van't Laar
Journal:  Diabetologia       Date:  1982-06       Impact factor: 10.122

4.  Mechanism of action of gemfibrozil on lipoprotein metabolism.

Authors:  K Saku; P S Gartside; B A Hynd; M L Kashyap
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

5.  Metabolism of very low- and low-density lipoproteins isolated from normolipidaemic type 2 (non-insulin-dependent) diabetic patients by human monocyte-derived macrophages.

Authors:  R L Klein; T J Lyons; M F Lopes-Virella
Journal:  Diabetologia       Date:  1990-05       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.